-

Preceptis Medical Selects AcuityMD for Expansion of Breakthrough In-Office Pediatric Ear Tube Device

AcuityMD’s data and insights drive commercial growth of important new option to families seeking alternatives for routine ear tube placement in millions of children

BOSTON--(BUSINESS WIRE)--In recognition of Children’s Health Month, AcuityMD, the AI platform for MedTech, announced that Preceptis Medical has selected its platform to support an expanded market launch of the Hummingbird® Tympanostomy Tube System (TTS). TTS offers a unique approach for pediatric ear tube placement in the office without the need for the operating room or general anesthesia. Preceptis Medical, a medical device company focused on office-based options for pediatric patients, chose AcuityMD for its deep industry expertise, comprehensive market data, and AI-driven insights to guide commercial decision making.

AcuityMD will help us engage with the right surgeons, and create greater awareness amongst payers, pediatricians, and parents about our unique solution.

Share

“We are an emerging company focused on growth through expanding patient access, and needed a powerful technology platform that would allow our team to work smarter, faster, and make informed decisions,” said David Carey, CEO of Preceptis Medical. “Our early market release demonstrated strong adoption and the need to further expand our footprint in the market. The platform offers insights on the right physicians to engage, how to hire strategically, set up smarter sales territories, and make better decisions at every step.”

Millions of Children Benefit

Approximately one million children annually will undergo ear tube procedures in the U.S., and by age three, one out of every 15 children will have tubes. Patients usually undergo the procedure in an operating room, which can be costly, have more risk, and be restrictive for many families. Further, both parents and pediatricians want to avoid exposing children to general anesthesia when possible, making the Hummingbird office procedure a simpler and preferred option.

According to Shelagh A. Cofer, M.D., a pediatric otolaryngologist and surgeon at Mayo Clinic in Minnesota who participated in a clinical trial with Preceptis Medical, the Hummingbird TTS is a 'single-pass' tool because it is designed to reduce steps and enable ear tube cases to be performed quickly in the office versus the operating room. “It's a revolutionary step forward for our field," said Dr. Cofer.

Carey concluded, “AcuityMD is the cornerstone of our Hummingbird Catalyst program, where we partner with customers to increase Hummingbird awareness and access in the community. AcuityMD will help us engage with the right surgeons, and create greater awareness amongst payers, pediatricians, and parents about our unique solution.”

To learn more about how AcuityMD enables Preceptis Medical and other MedTech companies to expand access to their breakthrough devices, visit www.acuitymd.com.

About AcuityMD
AcuityMD is the AI platform for MedTech and trusted by more than 400 MedTech companies – including six of the top 10. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD was named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for AcuityMD
+1 (610) 420-3413
lbarbadora@barbadoraink.com

AcuityMD


Release Versions

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for AcuityMD
+1 (610) 420-3413
lbarbadora@barbadoraink.com

Social Media Profiles
More News From AcuityMD

AcuityMD Ranked 57th Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform for MedTech, today announced that it ranked number 57 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing tech companies in North America, now in its 32nd year. AcuityMD grew 1,306% from 2022 to 2025. AcuityMD’s Co-Founder and CEO, Mike Monovoukas, credits the company’s sizable revenue growth to a growing shift across the medical device industry, as commercial teams adopt AI to better understand where care is happening an...

Channel Medsystems Brings Women New, Minimally Invasive Alternative Treatment with AcuityAI

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform trusted by over 500 MedTech companies, today announced its partnership with Channel Medsystems, a medical technology (medtech) company dedicated to transforming women’s healthcare globally to commercially relaunch Cerene Endometrial Cryotherapy. Cerene is a non-hormonal, incision-free endometrial cryotherapy treatment designed to reduce heavy menstrual bleeding (menorrhagia), which affects one in five or 10 million women in the U.S.Despite devel...

AcuityMD Brings Early Signals to AcuityAI, Helping MedTech Sales Teams Spot Changes in Physician Activity Sooner

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform for MedTech, today announced the availability of Early Signals in AcuityAI, giving commercial teams earlier visibility into potential changes in healthcare provider (HCP) procedure activity. Drawing on recent medical claims data, AcuityAI can identify early indicators that a physician may have started performing a procedure they had not performed previously. This intelligence also helps sales reps target new physicians and engage them ahead of...
Back to Newsroom